Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ECHELON-2 Ushers In Another New Adcetris Indication For Seattle Genetics

Executive Summary

The combination of Adcetris with chemotherapy improved progression-free and overall survival in peripheral T-cell lymphoma. Filing is expected soon, and approval will help the product reach blockbuster status.

You may also be interested in...



Top Financings: 2018 Was A Remarkable Year For Biopharma Fundraising

Highlights from the past year's financings include BeiGene's $800m follow-on offering in the US and $903m Hong Kong IPO, Moderna's $560m Series G round and $604m IPO, and Allogene's $300m Series A and $373m IPO.

VelosBio CEO: Series A Success Shows Investors Back His ADC Formula

VelosBio's well-backed Series A funding round showed that investors believe his team has identified the right combination of cancer target, linker and payload for creating a successful novel ADC, the biotech's CEO told Scrip.

Enfortumab Progresses As US Accelerated Approval Eyed In Urothelial Cancer

Astellas and Seattle Genetics now expect key top-line data on their antibody-drug conjugate in urothelial cancer in the first half of next year, as pivotal trials in support of a planned US accelerated approval progress.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC123928

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel